EMA committee recommends Lilly's oral GLP-1 Foundayo for obesity and type 2 diabetes

Eli Lilly and Company's once-daily obesity pill moved a step closer to the European market after the European Medicines Agency's human medicines committee recommended Foundayo (orforglipron) for marketing authorization in the European Union. The Committee for Medicinal Products for Human Use (CHMP) adopted its positive opinion on Oct. 15 at the close of its Oct. 12-15 meeting in Amsterdam, and the agency published the outcome on Oct. 16. The recommendation covers weight management and the treatment of type 2 diabetes in adults, and the final decision now rests with the European Commission.

How the medicine works

GLP-1 receptor agonists mimic a gut hormone that stimulates insulin release when blood sugar rises, slows stomach emptying and reduces appetite. Most medicines in the class are peptides delivered by injection. Orforglipron is a small, non-peptide molecule designed to be swallowed as a tablet, and the U.S. label allows it to be taken at any time of day without food or water restrictions. In its meeting summary, the EMA described Foundayo as an alternative to injectable and other oral GLP-1 receptor agonists.

The U.S. Food and Drug Administration approved Foundayo for weight loss on April 1, 2026. Lilly's approval announcement cited ATTAIN-1, a 72-week, placebo-controlled trial of 3,127 adults in 10 countries. Participants on the highest dose who stayed on treatment lost 12.4% of body weight on average, compared with 0.9% on placebo. Counting all randomized participants regardless of whether they completed treatment, the figures were 11.1% and 2.1%. A companion study, ATTAIN-2, enrolled more than 1,600 participants across 11 countries.

For diabetes, Lilly's earlier ACHIEVE-1 trial in 559 adults found A1C reductions of 1.3% to 1.6% over 40 weeks from a baseline of 8.0%, versus 0.1% on placebo. The EMA concluded that the medicine delivers a clinically relevant effect on blood sugar control and a beneficial effect on body weight when combined with diet and exercise.

Industry implications

A favorable CHMP opinion is usually the decisive step in the EU's centralized procedure. The European Commission typically issues a legally binding decision within about two months, and the authorization then applies across all 27 member states plus Iceland, Liechtenstein and Norway. Actual launch timing, however, depends on country-by-country pricing and reimbursement talks, which in Europe can take months or years and often restrict obesity drugs to narrower patient groups than the label allows.

The recommendation also signals regulatory comfort with an oral, non-peptide approach to a class built on injectables. For prescribers, a tablet with no fasting rules could simplify treatment for patients who avoid needles or struggle with the strict dosing conditions attached to other oral options. For payers, the question shifts from whether oral GLP-1 therapy works to where it sits in treatment pathways relative to injectables with longer track records and outcomes data.

The same CHMP meeting recommended five other new medicines, including Revolution Medicines' Rasonque for previously treated metastatic pancreatic cancer and the orphan medicine Yuviwel (navepegritide) for children with achondroplasia, underscoring a busy autumn cycle for the agency.

Competitive and supply chain implications

Foundayo enters a European GLP-1 field led by Novo Nordisk, whose oral semaglutide, Rybelsus, is already authorized in the EU for type 2 diabetes, and by injectable therapies from both Novo Nordisk and Lilly. A second company with an oral option for both diabetes and weight management widens choice for health systems that have dealt with injectable shortages in recent years.

Manufacturing is where a small molecule differs most. Peptide GLP-1 drugs rely on complex synthesis and, for injectables, on fill-finish lines and pen devices that have been bottlenecks. As a small molecule, orforglipron can be made through chemical synthesis and conventional tableting. When it reported ACHIEVE-1 results in April 2025, Lilly said it was confident it could launch the drug worldwide without supply constraints if approved. Lilly said in April 2026 that orforglipron had been submitted for weight management or type 2 diabetes in more than 40 countries, so European demand will draw on the same global network serving the U.S. and other markets.

For contract manufacturers, packaging suppliers and pharmacy distributors, a tablet format means bottles and blister packs instead of cold-chain pens, which may reduce storage and logistics demands at wholesale and pharmacy level.

Regional implications

Within Europe, the effect will vary sharply by country. Health technology assessment bodies in Germany, France, Italy, Spain and the Nordic countries each set their own rules on whether obesity treatment is reimbursed, and several exclude weight-loss medicines from standard coverage. The type 2 diabetes indication is likely to face fewer reimbursement barriers because diabetes therapies are routinely covered, which may make diabetes the first route to broad patient access.

In the U.S., Lilly began shipping Foundayo through its LillyDirect platform in April, with a self-pay price starting at $149 a month for the lowest dose. European prices will be set through national negotiations and are not yet public. Outside Europe, the CHMP view may also inform regulators in markets that reference EMA decisions in their own reviews.

What comes next

• A European Commission decision on marketing authorization, expected within roughly two months of the Oct. 15 opinion.
• Publication of the European public assessment report and full product information after the Commission decision.
• National pricing and reimbursement filings in individual EU member states, starting with the largest markets.
• Further regulatory decisions in the other markets where Lilly has filed orforglipron for weight management or type 2 diabetes.
• Additional clinical data releases from the orforglipron program, including longer-term and cardiovascular analyses.

Sources

• European Medicines Agency: Meeting highlights from the CHMP, 12-15 October 2026
• European Medicines Agency: Foundayo (orforglipron) summary of opinion
• Eli Lilly and Company: FDA approves Lilly's Foundayo (orforglipron)
• Eli Lilly and Company: ACHIEVE-1 Phase 3 results for orforglipron

Image: Eli Lilly and Company Corporate Center in Indianapolis, by Paul Sableman via Wikimedia Commons, CC BY 2.0. Cropped and edited by Credence Research.